All In Biotech

Drug Trial Radar · NCT04684940

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Active or Prior Inhibitors

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Dec 10, 2020

Primary completion

Apr 20, 2026

Study completion Apr 20, 2026

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Dec 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase I/II clinical study will evaluate the safety and efficacy of valoctocogene roxaparvovec in patients with severe haemophilia A and inhibitors to FVIII. Part A of the study will involve subjects who have active inhibitors to FVIII, and Part B involving subjects with a prior history of inhibitors.

Conditions

  • Hemophilia A With Inhibitor
  • Hemophilia A With Anti Factor VIII

Interventions

  • Valoctocogene roxaparvovecBiological

    Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 after administration of BMN 270.Time frame: 60 months

Locations

9 sites in 7 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Hemocentro Da UNICAMP

    Campinas, Brazil

  • Chaim Sheba Medical Center

    Ramat Gan, Israel

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea

  • Kaohsiung Medical University - Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Ege University School of Medicine

    Izmir, Turkey (Türkiye)

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.